Shattuck Labs(US:STTK)2025-05-01 20:21Financial Performance - Cash balance as of March 31, 2025, was approximately $60.9 million, expected to fund operations into 2027[5] - Net loss for Q1 2025 was $13.7 million, or $0.27 per share, compared to a net loss of $18.5 million, or $0.37 per share, in Q1 2024, indicating an improvement of 26.5%[10] - Collaboration revenue for Q1 2025 was $0, down from $1.1 million in Q1 2024[10] - Total assets as of March 31, 2025, were $77.2 million, a decrease from $91.0 million as of December 31, 2024[16] Expenses - Research and Development (R&D) expenses for Q1 2025 were $9.9 million, down from $16.3 million in Q1 2024, representing a decrease of 39.1%[10] - General and Administrative (G&A) expenses for Q1 2025 were $4.5 million, compared to $4.9 million in Q1 2024, a decrease of 8.2%[10] Clinical Development - The company plans to initiate a Phase 1 clinical trial for SL-325 in Q3 2025, with the first patient expected to be enrolled in the same quarter[6] - Phase 1 enrollment completion for SL-325 is expected in Q2 2026[6] - The company is developing multiple preclinical DR3-based bispecific antibodies, with a lead candidate nomination planned for 2025[6] - Shattuck Labs reported no infusion-related reactions in preclinical studies of SL-325, with a No Observed Adverse Effect Level determined to be 100 mg/kg[6]